Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,797,903 papers from all fields of science
Search
Sign In
Create Free Account
Linomide
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
LS 2616
Broader (1)
roquinimex
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats
Jian-She Yang
,
Linghui Xu
,
B. Xiao
,
G. Hedlund
,
H. Link
Journal of Neuroimmunology
2004
Corpus ID: 25774826
Highly Cited
2000
Highly Cited
2000
Linomide in relapsing and secondary progressive MS
J. Wolinsky
,
Ponnada A. Narayana
,
+5 authors
H. C. Sullivan
Neurology
2000
Corpus ID: 261955215
Objective: To determine the safety and efficacy of roquinimex (linomide) in the management of relapsing-remitting and secondary…
Expand
Highly Cited
1997
Highly Cited
1997
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
I. Joseph
,
J. Nelson
,
S. Denmeade
,
J. Isaacs
Clinical Cancer Research
1997
Corpus ID: 28434423
In previous studies, we have demonstrated that androgen ablation-induced growth inhibition of androgen-responsive PC-82 and A-2…
Expand
Review
1997
Review
1997
Target to apoptosis: A hopeful weapon for prostate cancer
D. Tang
,
A. Porter
The Prostate
1997
Corpus ID: 34650290
Prostate cancer is the most commonly diagnosed neoplasm and the second leading cause of male death in this country. Multiple…
Expand
Highly Cited
1997
Highly Cited
1997
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
I. Joseph
,
J. Isaacs
Cancer Research
1997
Corpus ID: 1302802
Linomide is a p.o. active antiangiogenic agent that has been demonstrated to be effective in suppressing the in vivo growth of…
Expand
Highly Cited
1996
Highly Cited
1996
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide
D. Karussis
,
Z. Meiner
,
+4 authors
O. Abramsky
Neurology
1996
Corpus ID: 8640359
Linomide (quinoline-3-carboxamide) is a synthetic immunomodulator that increases the natural killer cell activity. We previously…
Expand
Highly Cited
1995
Highly Cited
1995
Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo
N. Zamzami
,
P. Marchetti
,
+4 authors
G. Kroemer
Journal of Experimental Medicine
1995
Corpus ID: 1686042
In a number of experimental systems in which lymphocyte depletion was induced by apoptosis-inducing manipulations, no apoptotic…
Expand
Highly Cited
1993
Highly Cited
1993
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
D. Karussis
,
D. Lehmann
,
+5 authors
O. Abramsky
Proceedings of the National Academy of Sciences…
1993
Corpus ID: 20164248
Linomide is a synthetic immunomodulator that enhances natural killer cell activity and significantly activates several…
Expand
Highly Cited
1993
Highly Cited
1993
Antiangiogenic effects of the quinoline-3-carboxamide linomide.
J. Vukanović
,
A. Passaniti
,
T. Hirata
,
R. Traystman
,
B. Hartley‐åsp
,
J. Isaacs
Cancer Research
1993
Corpus ID: 7453449
Linomide (N-phenylmethyl-1,2-dihydro-4-hydroxyl-1-methyl-2-oxoquinoline-3-carboxa mide) has a reproducible in vivo antitumor…
Expand
Highly Cited
1993
Highly Cited
1993
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide
MD D. M. Karussis
,
PhD D. Lehmann
,
+8 authors
S. Slavin
Annals of Neurology
1993
Corpus ID: 25405874
Linomide (LS‐2616, quinoline‐3‐carboxamide) is a synthetic immunomodulator that stimulates natural killer cell activity and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required